Found: 43
Select item for more details and to access through your institution.
Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime.
- Published in:
- 2002
- By:
- Publication type:
- journal article
Streptococcus pneumoniae in the USA: in vitro susceptibility and pharmacodynamic analysis.
- Published in:
- 2000
- By:
- Publication type:
- journal article
Evaluation of Factors Predictive of Efficacy Among Patients With Complicated Urinary Tract Infection and/or Acute Pyelonephritis.
- Published in:
- Open Forum Infectious Diseases, 2024, v. 11, n. 9, p. 1, doi. 10.1093/ofid/ofae375
- By:
- Publication type:
- Article
A Broken Antibiotic Market: Review of Strategies to Incentivize Drug Development.
- Published in:
- Open Forum Infectious Diseases, 2020, v. 7, n. 7, p. 1, doi. 10.1093/ofid/ofaa083
- By:
- Publication type:
- Article
Old In Vitro Antimicrobial Breakpoints Are Misleading Stewardship Efforts, Delaying Adoption of Innovative Therapies, and Harming Patients.
- Published in:
- Open Forum Infectious Diseases, 2020, v. 7, n. 7, p. 1, doi. 10.1093/ofid/ofaa084
- By:
- Publication type:
- Article
1591. Updated Fluoroquinolone MIC Breakpoints: Impact on Susceptibility Rates in the United States.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S580, doi. 10.1093/ofid/ofz360.1455
- By:
- Publication type:
- Article
1590. Updated Aminoglycoside (AG) MIC Breakpoints (BP) to Minimize Adverse Events and Improve Outcome: Impact on Susceptibility (S) Rates.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S580, doi. 10.1093/ofid/ofz360.1454
- By:
- Publication type:
- Article
1565. Characterization of Tebipenem (SPR859) Pharmacokinetics–Pharmacodynamics (PK-PD) for Efficacy Against Enterobacteriaceae in a One-Compartment In Vitro Infection Model.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S571, doi. 10.1093/ofid/ofz360.1429
- By:
- Publication type:
- Article
1534. Polymyxin Antimicrobial Susceptibility (AST) Testing and Breakpoints for P. aeruginosa, A. baumannii, and Enterobacteriaceae: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST).
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S559, doi. 10.1093/ofid/ofz360.1398
- By:
- Publication type:
- Article
733. Pharmacokinetic–Pharmacodynamic (PK–PD) Analyses for Alanine Aminotransferase (ALT) Using Phase 3 Data From Omadacycline (OMC)-Treated Patients.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S328, doi. 10.1093/ofid/ofz360.801
- By:
- Publication type:
- Article
Time for Precision: A World Without Susceptibility Breakpoints.
- Published in:
- Open Forum Infectious Diseases, 2018, v. 5, n. 12, p. N.PAG, doi. 10.1093/ofid/ofy282
- By:
- Publication type:
- Article
Antibacterial Drug Development: A New Approach Is Needed for the Field to Survive and Thrive.
- Published in:
- Antibiotics (2079-6382), 2020, v. 9, n. 7, p. 412, doi. 10.3390/antibiotics9070412
- By:
- Publication type:
- Article
Antibiotic bill doesn't GAIN enough ground.
- Published in:
- Nature Medicine, 2011, v. 17, n. 7, p. 772, doi. 10.1038/nm0711-772
- By:
- Publication type:
- Article
Isoniazid's Bactericidal Activity Ceases because of the Emergence of Resistance, Not Depletion of Mycobacterium tuberculosis in the Log Phase of Growth.
- Published in:
- Journal of Infectious Diseases, 2007, v. 195, n. 2, p. 194, doi. 10.1086/510247
- By:
- Publication type:
- Article
Pharmacokinetics of High-Dose Meropenem in Adult Cystic Fibrosis Patients.
- Published in:
- Chemotherapy (0009-3157), 2001, v. 47, n. 3, p. 153, doi. 10.1159/000063216
- By:
- Publication type:
- Article
Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.
- Published in:
- Clinical Infectious Diseases, 2018, v. 67, p. S293, doi. 10.1093/cid/ciy611
- By:
- Publication type:
- Article
Gatifloxacin Pharmacokinetics/Pharmacodynamics–based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.
- Published in:
- Clinical Infectious Diseases, 2018, v. 67, p. S274, doi. 10.1093/cid/ciy618
- By:
- Publication type:
- Article
Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia.
- Published in:
- Journal of Clinical Pharmacology, 2013, v. 53, n. 11, p. 1155, doi. 10.1002/jcph.153
- By:
- Publication type:
- Article
Monte Carlo Simulation in the Evaluation of Susceptibility Breakpoints: Predicting the Future.
- Published in:
- Pharmacotherapy, 2006, v. 26, n. 1, p. 129, doi. 10.1592/phco.2006.26.1.129
- By:
- Publication type:
- Article
Correction to: PK-PD Compass: bringing infectious diseases pharmacometrics to the patient’s bedside.
- Published in:
- 2018
- By:
- Publication type:
- Correction Notice
Relationships between Patient- and Institution-Specific Variables and Decreased Antimicrobial Susceptibility of Gram-Negative Pathogens.
- Published in:
- Clinical Infectious Diseases, 2003, v. 37, n. 3, p. 344, doi. 10.1086/375817
- By:
- Publication type:
- Article
Correspondence.
- Published in:
- 2001
- By:
- Publication type:
- Letter
Infectious Diseases Society of America Position Statement on Infectious Diseases Physicians and Hospital Pharmacists: Comment and Editorial.
- Published in:
- Clinical Infectious Diseases, 1998, v. 27, n. 1, p. 229, doi. 10.1086/517689
- By:
- Publication type:
- Article
Reply to Paul and Leibovici.
- Published in:
- 2018
- By:
- Publication type:
- journal article
White Paper: Developing Antimicrobial Drugs for Resistant Pathogens, Narrow-Spectrum Indications, and Unmet Needs.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Methodological features of clinical pharmacokinetic-pharmacodynamic studies of antibacterials and antifungals: a systematic review.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia.
- Published in:
- 2019
- By:
- Publication type:
- journal article
We can do better: a fresh look at echinocandin dosing.
- Published in:
- 2018
- By:
- Publication type:
- journal article
We can do better: a fresh look at echinocandin dosing.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Background and Rationale for Revised Clinical and Laboratory Standards Institute Interpretive Criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.
- Published in:
- Clinical Infectious Diseases, 2013, v. 56, n. 9, p. 1301
- By:
- Publication type:
- Article
In Vivo Activity of Oritavancin in Animal Infection Models and Rationale for a New Dosing Regimen in Humans.
- Published in:
- Clinical Infectious Diseases, 2012, v. 54, p. S220, doi. 10.1093/cid/cis001
- By:
- Publication type:
- Article
Application of Pharmacokinetic-Pharmacodynamic Modeling and the Justification of a Novel Fusidic Acid Dosing Regimen: Raising Lazarus From the Dead.
- Published in:
- Clinical Infectious Diseases, 2011, v. 52, n. Suppl 7, p. S513, doi. 10.1093/cid/cir166
- By:
- Publication type:
- Article
Reply to Donovan et al.
- Published in:
- 2010
- By:
- Publication type:
- Letter
Pharmacokinetic-Pharmacodynamic Considerations in the Design of Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia Studies: Look before You Leap!
- Published in:
- Clinical Infectious Diseases, 2010, v. 51, p. S103, doi. 10.1086/653057
- By:
- Publication type:
- Article
Daptomycin Exposure and the Probability of Elevations in the Creatine Phosphokinase Level: Data from a Randomized Trial of Patients with Bacteremia and Endocarditis.
- Published in:
- Clinical Infectious Diseases, 2010, v. 50, n. 12, p. 1568, doi. 10.1086/652767
- By:
- Publication type:
- Article
Use of Pharmacokinetics and Pharmacodynamics in a Failure Analysis of Community-Acquired Pneumonia: Implications for Future Clinical Trial Study Design.
- Published in:
- Clinical Infectious Diseases, 2008, v. 47, p. S225, doi. 10.1086/591427
- By:
- Publication type:
- Article
Back to the Future: Using Aminoglycosides Again and How to Dose Them Optimally.
- Published in:
- Clinical Infectious Diseases, 2007, v. 45, n. 6, p. 753, doi. 10.1086/520991
- By:
- Publication type:
- Article
Pharmacokinetics-Pharmacodynamics of Antimicrobial Therapy: It's Not Just for Mice Anymore.
- Published in:
- Clinical Infectious Diseases, 2007, v. 44, n. 1, p. 79, doi. 10.1086/510079
- By:
- Publication type:
- Article
Extended-Spectrum β-Lactamases and Clinical Outcomes: Current Data.
- Published in:
- Clinical Infectious Diseases, 2006, v. 42, p. S164, doi. 10.1086/500663
- By:
- Publication type:
- Article
The Pharmacokinetic and Pharmacodynamic Profile of Tigecycline.
- Published in:
- Clinical Infectious Diseases, 2005, v. 41, p. S333, doi. 10.1086/431674
- By:
- Publication type:
- Article
Antimicrobial Safety: Focus on Fluoroquinolones.
- Published in:
- Clinical Infectious Diseases, 2005, v. 41, p. S144, doi. 10.1086/428055
- By:
- Publication type:
- Article
Use of Pharmacodynamic End Points in the Evaluation of Gatifloxacin for the Treatment of Acute Maxillary Sinusitis.
- Published in:
- Clinical Infectious Diseases, 2004, v. 38, n. 11, p. 1513, doi. 10.1086/420739
- By:
- Publication type:
- Article
Antimicrobial treatment guidelines for acute bacterial rhinosinusitis.
- Published in:
- 2004
- By:
- Publication type:
- journal article